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Background: Influenza virus is still a severe respiratory disease affecting human and other species. As conventional
drugs are not recommended for long time because of side effects and drug resistance occurrence, traditional
medication has been focused as alternative remedy. HESA-A is a natural compound from herbal-marine origin.
Previous studies have reported the therapeutic properties of HESA-A on psoriasis vulgaris and different types of
cancers and we also showed its anti-inflammatory effects against influenza A infection.
Methods: This study was designed to investigate the potential properties of HESA-A as prophylaxis or treatment.
To investigate the prophylaxis or treatment activities of HESA-A, Madin-Darby Canine Kidney (MDCK) cells were
exposed to HESA-A and influenza A virus in different manners of exposure and different time intervals. The results
were evaluated by MTT and HA assays.
Results: It was found that HESA-A is much more effective against influenza cytopathic effects when it is applied for
prophylaxis and also in concurrent treatment (p ≤ 0.05) but not in post-infection treatment (p ≥ 0.05).
Conclusion: In conclusion, HESA-A is significantly effective against influenza replication in prophylaxis application
affecting the virus penetration/adsorption to the cell without any toxic effect on the cell viability.
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Influenza A virus as a member of the Orthomyxoviridea
family results in significant morbidity and high rates of
mortality worldwide annually. Vaccines which are the best
option to prevent this infection cannot be trusted because
of the lag time between virus identification and vaccine
distribution which may cause devastating outcomes.
Conventional approved antiviral drugs such as amantadine
and oseltamivir [1] which are helpful to control the spread
of influenza disease from the host cell [2] may not be
suggested any longer due to various genetic drift and
shift mutations which cause alterations in the antibody-
targeted surface glycoproteins [3] and negative side effects
and rapid emergence of resistant variants [4,5]. Therefore,
they are not recommended for uncontrolled usage [6].
Thus, additional antiviral alternatives preferably with
natural origin easily available for the prevention/treatment* Correspondence: aiini@upm.my
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demanded.
HESA-A is an active natural biological compound
from herbal-marine origin, with a general composition
of organic, inorganic and aqueous fractions [7]. Previous
studies have reported the therapeutic properties of HESA-
A against psoriasis vulgaris, breast cancer and choroidal
metastasis [8-10]. In our previous study on HESA-A,
we showed the antiviral activity of this compound on
influenza replication by affecting hypercytokinemia de-
creasing TNF-α and IL-6 expression levels [11]. In the
current study we evaluated the preventive or treatment
activity of HESA-A on influenza replication in different
exposures and time intervals.Methods
Reagents and chemicals
Cell culture media and penicillin-streptomycin solution
100× were purchased from Mediatech Cellgro Company
(Northbrook, Illinois, USA). Fetal bovine serum (FBS) was
purchased from PAA Laboratories (Pasching, Austria).al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Tehran University of Medical Sciences, Tehran, IRAN.
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide, MTT), and Tosylamide Phenylethyl Chloromethyl
Keton-treated Trypsin (Trypsin TPCK) were purchased
from Sigma (Saint Louis, Missouri, USA).
HESA-A preparation
Briefly, it was dissolved in normal saline, shaken for 30
minutes and filtered to become homogenate. Prior to its
use, the stock solution (0.8 mg/ml, pH 7.4) was sterilized
through 0.22 μm syringe filter [12]. It was diluted with
DMEM to 0.025 mg/ml concentration as EC50 [11].
Cell culture and influenza A virus propagation
Influenza A virus strain New Jersey/8/76; H1N1 [A/NJ
(H1N1)] was purchased from American Type Culture
Collection (ATCC) (reference number: VR-897™) which
was propagated on Madin Darby canine kidney (MDCK)
cell line (CCL-34™). Cells were grown in Dulbecco's
modified Eagle’s medium (DMEM) containing 10% heat-
inactivated FBS, 100 units/ml penicillin G and 100 μg/ml
streptomycin. Cultured cells were incubated at 37°C in the
presence of 5% CO2. To propagate influenza A virus, cells
were washed with PBS to remove residual FBS and were
infected with influenza A virus at MOI of 0.5 in serum-
free DMEM for 60 min at 37°C (adsorption phase).
Progeny virus was harvested three days post-infection.
Standard hemagglutination test (HA) was carried out to
measure the viral titer [11].
HESA-A anti-viral effect on the virus
MDCK cells seeded in 96-well plate were exposed to dif-
ferent combination treatments of HESA-A and influenza
A virus (100 TCID50/0.1 ml) in different time intervals.
HESA-A in a non-cytotoxic concentration was used for
antiviral assays. It was added to MDCK cells before,
concomitantly with or after H1N1 infection in 1, 8 and
24 hr time points. In brief, monolayers of MDCK cells
were treated with HESA-A for 1, 8 or 24 hr, which was
washed away before infection with H1N1 for 1 hr (pre-
treatment assay), HESA-A and H1N1 were added to
the cell layer together during the 1, 8 or 24 hr infection
period (co-treatment assay), or HESA-A was added for
1, 8 or 24 hr right after the infection period for 1 hr
(post-treatment assay). After all the treatments in allo-
cated time, cells were washed with PBS and covered with
medium containing Trypsin_TPCK (1 μg/ml) for 48 hr.
MTT cell viability assay
MDCK cells were incubated in 96-well microplate (Nunc,
Denmark) for 24 hr at 37°C to reach the confluency.
Following treatments based on the experimental design,
colorimetric MTT assay was performed according toMehrbod et al. [13]. Briefly, the media was removed
and 100 μl of 1× MTT (3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide, Sigma) was added to
each well. Following incubation at 37°C for 2–3 hr, 100 μl
of DMSO was added and mixed thoroughly to release
the colour. The absorbance of colour in the solution
was analyzed at 540 nm with microplate reader machine
(BioTek EL 800, US) to calculate viability of the cells by
one way ANOVA, SPSS.
Hemagglutination assay
To evaluate the presence of the virus in cell culture, either
virus-inoculated or combined-treated samples, super-
natants of the culture media were exposed to chicken
red blood cells (cRBCs) (0.5%). The assay was carried
out as described previously by Mehrbod et al. [13].
The significant differences were analyzed using one
way ANOVA, SPSS.
Statistical analysis
The data expressed as mean ± SD was gathered and ana-
lyzed using analysis of variance (ANOVA) Tukey post-hoc
test (SPSS 18.0). Sample values between different groups
and treatments with p ≤ 0.05 were considered statistically
significant.
Results and discussion
In this experiment, to evaluate the protective effect of
non-toxic concentration of HESA-A (0.025 mg/ml) in
combination treatments with H1N1 in different time
points, MTT viability test was conducted following in-
cubation periods. As expected, HESA-A treatment in
0.025 mg/ml concentration did not show any signifi-
cant difference with the control (p ≥ 0.05), while H1N1
treatments caused significant decrements in cell viability
as compared to the control (p ≤ 0.05). However, there
was significant increment in optical densities (ODs) in
different combination exposures as compared to virus-
inoculated sample (p ≤ 0.05) except for post-treatments
(p ≥ 0.05). The results are shown in Figure 1.
Based on hemagglutination titration, the inhibitory effect
of HESA-A on viral activity was shown by highly significant
reduction in Log HA titre in all combination treatments
(p < 0.01). The results are shown in Figure 2.
Influenza A virus is the major cause of respiratory tract
infections in a variety of species [14]. Unsuccessful treat-
ment of this disease is related to its constant evolving
genome which makes it extremely difficult to develop
effective vaccines as well as antiviral drugs [15]. Thus,
developing novel anti-influenza compounds, preferably
of natural origin and low side effects are required [16,17].
HESA-A which is a patented natural product in IRAN,
has been used against different types of diseases like wide
range of cancers, psoriasis vulgaris and autoimmune
Figure 1 Cell viability in combination treatments. Data shows the MTT assay results for cell viability of HESA-A treatments against influenza A
virus H1N1 CPE in different exposure types and time points. Data are presented as mean ± SD. *: Significantly different from values obtained for
co- & pre-treatments as compared to the virus sample (p < 0.05).
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improving the patients’ quality of life [9,10,18]. In our
previous research on HESA-A focusing on its antiviral
activity against influenza A virus H1N1, the EC50 (ef-
fective concentration) of this compound was obtained
at 0.025 mg/ml with no cytotoxic effect on MDCK cells
and its anti-inflammatory effects against two important
inflammatory cytokines; TNF-α and IL-6 was verified
in genome and protein level in 1 hr exposure time. TheFigure 2 Log HA titer reduction in HESA-A treatments against H1N1.
treatments as compared to the H1N1 sample. Data are presented as mean ± S
treatments as compared to the virus sample (p < 0.01).results showed the inhibitory effects of HESA-A on H1N1
infection. In the present study we confirmed the inhibitory
effects of HESA-A on influenza infection by different
types of combination treatments in different time points.
Data from viability test showed that co- & pre-treatments
but not post-treatment, even in short incubation times
protected the cell viability against H1N1 CPE significantly
(p ≤ 0.05). However, data from HA assay showed highly
significant decrements in HA titers in all combinationThe HA data showed highly significant decrements in all combination
D. **: Highly significantly different from values obtained for combination
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results it is postulated that post-treatment cannot protect
the cell viability from viral CPE, therefore, the decrease
in HA titer in this type of exposure means no viable
cell presence to support the viral replication. In conclu-
sion, supporting achievements from previous study which
showed the effects of HESA much stronger than amanta-
dine and also supporting data from current study, suggest
that HESA-A as a natural product has the potential of
supplementary medication or alternative to antiviral
agents to inhibit influenza infection especially in the
first steps of its infection cycle by prophylactic effects
affecting the virus penetration/adsorption. More detailed
investigation on viral and cellular pathways could be of
interest to evaluate the localization of function of HESA-A
on virus-host interaction system.
Conclusion
In conclusion, supporting achievements from previous
study which showed the effects of HESA much stronger
than amantadine and also supporting data from current
study, suggest that HESA-A as a natural product has the
potential of supplementary medication or alternative to
antiviral agents to inhibit influenza infection especially
in the first steps of its infection cycle by prophylactic
effects affecting the virus penetration/adsorption. More
detailed investigation on viral and cellular pathways could
be of interest to evaluate the localization of function of
HESA-A on virus-host interaction system.
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